Comparison
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875 vs 3q26 Microduplication Syndrome C4755319
Clinical comparison between 46 XX Disorder OF Sex Development Induced BY Endogenous Maternal Derived Androgen and 3q26 Microduplication Syndrome for differential diagnosis and treatment planning.
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
A condition where hormones from the mother cross the placenta and cause atypical development in an XX fetus. It is present at birth. Management involves pediatric specialists and may include hormone therapy.
3q26 Microduplication Syndrome C4755319
A genetic condition involving extra genetic material at chromosome 3q26, which can cause developmental delays and other features depending on specific genes involved.
6 comparison axes
Onset
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
Variable
3q26 Microduplication Syndrome C4755319
0-null
Onset patterns differ
Severity
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
severe
3q26 Microduplication Syndrome C4755319
moderate
Different severity levels
Chronic
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
Chronic
3q26 Microduplication Syndrome C4755319
Chronic
Differing course
Communicable
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
No
3q26 Microduplication Syndrome C4755319
No
Different transmission
Body System
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
reproductive
3q26 Microduplication Syndrome C4755319
congenital
Same/different system
Category
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
endocrine
3q26 Microduplication Syndrome C4755319
genetic
Different category
Bottom line
46-xx-disorder-of-sex-development-induced-by-endogenous-maternal-derived-androgen-C5679875 and 3q26-microduplication-syndrome-C4755319 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875 | 3q26 Microduplication Syndrome C4755319 | Discriminating power |
|---|---|---|---|
| Genital development | Atypical genital development may be present at birth in an XX fetus. | Genital atypicality is not established by the supplied description. | Moderate |
| Developmental delay | Developmental delay is not described as a defining feature. | Developmental delay may occur, depending on genes involved. | Moderate |
| System pattern | Primarily framed as a reproductive and endocrine condition. | Framed as a congenital genetic condition with variable features. | High |
When to favor each condition
Choose 46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875 when
XX infant with atypical genital development and suspected maternal androgen exposure
The history and phenotype align with an endocrine disorder of sex development rather than a chromosomal duplication.
Moderate
Need for pediatric endocrine and DSD specialist assessment
Source management centers on pediatric specialists and possible hormone therapy, without specified regimens.
Moderate
No established chromosomal explanation after initial evaluation
A negative or unrelated genetic result may keep maternal androgen exposure under consideration.
Low
Choose 3q26 Microduplication Syndrome C4755319 when
Developmental delay with suspected chromosomal copy-number change
The description specifically links extra 3q26 material to developmental differences.
Moderate
Multiple congenital or developmental features without a clear endocrine history
A genetic category is more consistent when features extend beyond sex development.
Low
Family or prenatal concern about chromosome 3q26
Targeted genetic interpretation is needed; clinical significance depends on the genes involved.
Moderate
How key tests differ
| Test | 46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875 | 3q26 Microduplication Syndrome C4755319 | Interpretation |
|---|---|---|---|
| Karyotype or sex-chromosome assessment | Concept is defined in an XX context; testing confirms chromosomal sex but not the cause. | Standard karyotype may miss a microduplication. | An XX result does not distinguish these conditions by itself. |
| Chromosomal microarray | Not expected to identify maternal androgen exposure. | May detect extra material at 3q26, requiring gene-level interpretation. | A positive finding supports the genetic condition but does not prove clinical effects. |
| Endocrine evaluation | May be used to investigate androgen exposure; no cutoff is supplied. | No characteristic endocrine abnormality is established here. | Abnormal hormone results are findings, not a complete diagnosis. |
Prognosis comparison
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
- Outcome
- Long-term outcome is not established; specialist follow-up may be ongoing.
- Factors
- Timing and degree of androgen exposure and individual development, none quantified here.
3q26 Microduplication Syndrome C4755319
- Outcome
- Outcome is variable and not established from the supplied description.
- Factors
- Size, genes involved, and associated developmental features.
Time frame: From birth or recognition through long-term follow-up; exact course is not established.
Accurate diagnosis, associated findings, and access to coordinated care.
Complications comparison
| Complication | Presentation |
|---|---|
| Psychosocial impact | Sex-development differences may affect identity, family communication, and care decisions. Developmental differences may affect learning, independence, and family support needs. Impact is individual and not quantified in the source. |
| Associated medical complexity | May require coordinated endocrine and pediatric follow-up. Features and needs vary with the duplicated genes. Specific complication rates are not established. |
| Diagnostic uncertainty | Cause and extent require specialist confirmation. Clinical meaning of a duplication may be uncertain. Neither label should be assigned from one abnormal result alone. |
Patient education highlights
- HighDistinct causes
One condition concerns hormone exposure in an XX fetus; the other concerns extra chromosome 3q26 material.
- HighSpecialist interpretation
Diagnosis, testing, and any hormone therapy require clinicians; doses and cutoffs are not provided here.
- MediumVariable course
Both are described as chronic, but features and support needs can differ widely.